Condition (MeSH)
Citrullinemia
ClinicalTrials.gov lists 12 trials for Citrullinemia or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
12 of the 12 trials are tagged with Citrullinemia itself; the rest are tagged with a narrower condition beneath it.
When did Citrullinemia trials start? (8)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Not applicable
- Observational
Top of scale: 3
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2022 | 3 |
| 2021 | 1 |
| 2020 | 1 |
| 2018 | 1 |
| 2012 | 1 |
| 2011 | 3 |
| 2008 | 1 |
| 2007 | 1 |
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 12 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Citrullinemia trials in? (4)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 2 |
| Not applicable | 1 |
| Observational | 8 |
How many Citrullinemia trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 2 |
| Active, not recruiting | 2 |
| Completed | 5 |
| Terminated | 2 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Citrullinemia trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Cytonet GmbH & Co. KG | 1 |
| National Human Genome Research Institute (NHGRI) | 1 |
Interventions as named in the registry (3)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Human Heterologous Liver Cells | 1 |
| Standard of Care Therapy | 1 |
| human hepatocyte transplantation | 1 |
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which publications cover Citrullinemia? (6)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Early prediction of phenotypic severity in Citrullinemia Type 1. | Annals of clinical and translational neurology | 2019 | Yes |
| Biochemical markers and neuropsychological functioning in distal urea cycle disorders. | Journal of inherited metabolic disease | 2018 | Yes |
| Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial. | JAMA oncology | 2017 | Yes |
| Metabolic therapy with PEG-arginase induces a sustained complete remission in immunotherapy-resistant melanoma. | Journal of hematology & oncology | 2018 | No |
| Cross-sectional multicenter study of patients with urea cycle disorders in the United States. | Molecular genetics and metabolism | 2008 | No |
Showing 5 of 6 publications.
Prevalence (3)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Citrullinemia | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Citrullinemia | Point prevalence | Unknown | Worldwide | Not stated | Exact |
| Citrullinemia | Point prevalence | Unknown | Worldwide | Not stated | Unspecified |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Citrullinemia | 187 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Citrullinemia | 187 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials and sub-conditions in mesh.